Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
NCT03732833 is registered in ClinicalTrials.gov with Medy-Tox as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
- Lead sponsor
- Medy-Tox
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 5, 2018
- Completion date
- January 25, 2021
- Enrollment
- 425 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
glabellar lines, lateral canthal lines